Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
    Meeting Abstract

    Dummer, R.; Long, G. V.; Pavlick, A. C.; Postow, M. A.; Ribas, A.; Robert, C.; Scolyer, R. A.; Taube, J. M.; Tetzlaff, M.; Su, S. C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
    Meeting Abstract

    Tawbi, H. A.; Forsyth, P. A.; Hodi, F. S.; Algazi, A.; Hamid, O.; Lao, C. D.; Moschos, S. J.; Atkins, M. B.; Lewis, K.; Postow, M. A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
    Meeting Abstract

    Bhave, P.; Ahmed, T.; Shoushtari, A. N.; Zaremba, A.; Versluis, J. M.; Mangana, J.; Weichenthal, M.; Si, L.; Lesimple, T.; Robert, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI)
    Meeting Abstract

    Dimitriou, F.; Namikawa, K.; Teterycz, P.; Reijers, I. L. M.; Buchbinder, E.; Soon, J.; Zimmer, L.; Mooradian, M.; Vitale, M. G.; Armstrong, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers
    Meeting Abstract

    Posner, M. R.; Ho, A. L.; Niu, J.; Nabell, L.; Leidner, R. S.; Nieva, J.; Richardson, D. L.; Pearson, A. T.; Wang, D.; Chung, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201
    Meeting Abstract

    Mora, J.; Bear, M.; Chan, G.; Morgenstern, D. A.; Nysom, K.; Tornøe, K.; Losic, N.; Kushner, B.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
    Meeting Abstract

    Altan, M.; Patnaik, A.; Barve, M. A.; Dunn, L.; Cobb, P. W.; Rosenberg, A.; Sharma, S.; Sukari, A.; Lee, Z.; Marcondes, M. Q.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results
    Meeting Abstract

    Naing, A.; Rosen, L.; Camidge, R. D.; Khalil, D.; Davies, J.; Miles, D.; Patel, M.; Cockle, P.; Champion, B.; Krige, D.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial
    Meeting Abstract

    Özcan, M.; Jin, J.; Szomor, Á.; Panayiotidis, P.; Yoon, D. H.; Tyczynska, A. M.; Mongay Soler, L.; Cao, A.; Hiemeyer, F.; Childs, B. H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Gavocabtagene autoleucel (gavo-cel, TC-210) dose escalation in refractory mesothelin-expressing solid tumors
    Meeting Abstract

    Hong, D. S.; SciMentum, S. L.; Tanyi, J.; MacMullen, L.; Jalbert, L.; Muzithras, V. P.; Zikaras, K.; Cao, L.; O'Cearbhaill, R. E.; Quintás-Cardama, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save